CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

Moderna said on Friday it had filed a marketing application for an updated COVID vaccine to the U.S. Food and Drug ...

Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine ...

The updated warnings highlight a rare risk of heart inflammation in teen boys and young men, CBS News reported. The warning ...

Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine ...

The revised version of the vaccine, marketed as Spikevax, follows FDA guidance recommending that this year’s shots target ...

Moderna isn’t giving up on the combo shot entirely—it plans to resubmit later this year after it collects more data from its ...

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

Moderna Inc. said it has “voluntarily” withdrawn its application for regulatory approval for its combination Covid and flu ...

The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from ...

Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.